Skip to content
Pharma Observatory a Scientist.com platform

Organization (Academic)

Virginia Polytechnic Institute and State University

ClinicalTrials.gov lists Virginia Polytechnic Institute and State University as lead sponsor of 125 trials. It has 14 active development programs and 6 approved assets.

US Academic
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

27 0 2001 2027

Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

2026 is partial: 14 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 14 in 2026 and about 14 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (5 to 20), forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. The 2026 forecast is below the 14 already registered with a 2026 start date: at the cutoff, 4 trials were already registered to start in October to December, more than the method's monthly average allows for, and the method does not use those planned starts.

Logo Virginia Tech, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.

This page covers Virginia Polytechnic Institute and State University: 125 lead-sponsored trials and 0 legal-entity registrations.

Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.

Get the Virginia Polytechnic Institute and State University report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (153)

Shown in this order: most trials first.

Disease areas
Disease area Trials
Pain 21
Obesity 18
Substance-Related Disorders 18
Diabetes Mellitus 13
Anxiety Disorders 9

Trials by start year as sponsor or collaborator (22)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Show the table of trials by start year as sponsor or collaborator
Trials by start year as sponsor or collaborator
Year Trials started
2026 (partial year) 14
2025 12
2024 20
2023 27
2022 26
2021 13
2020 5
2019 10
2018 9
2017 7

Prediction, not a registry value: median 36 months or more (the model's horizon) from start to primary completion across 17 trials still running at the 2026-10-09 snapshot; 11 of 17 predicted trials reach the 36-month horizon; registered median of 26 months across 91 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

Active development programs (14)

Shown in this order: max phase, then active trials.

Active development programs
Drug Disease area Max phase Trials
Vitamin D 5000 UNT Malnutrition Early 1 1
Vitamin D 5000 UNT Vitamin D Deficiency Early 1 1
Vitamin D 10000 UNT Vitamin D Deficiency Early 1 1
Vitamin D 10000 UNT Malnutrition Early 1 1
Loteprednol Etabonate Ophthalmic Gel [Lotemax] Macular Degeneration Not reported 1

Approved assets (6)

Shown in this order: max phase first.

Approved assets
Drug Trials
Triamcinolone Acetonide 40mg/mL 1
NEBIVOLOL 1
Olmesartan Medoxomil 1
Choline 3
Buprenorphine 1

Sponsor delivery record (1)

Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.

Sponsor delivery record
Enrollment Timeline
34% hit target (n=59) 30% on time (n=60)

Journals published in (396)

Shown in this order: most published in first.

Journals published in
Journal Publications
Gastroenterology 26
Gastrointestinal endoscopy 15
The American journal of gastroenterology 13
Gut 12
Inflammatory bowel diseases 12

US granted patents (1)

Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.

US granted patents
US patents granted Granted in the last 5 years Most recent grant
76 6 2024-06-11

Organization relationships (14)

Shown in this order: most evidence first.

Organization relationships
Related organization Relationship Evidence
Government of the United States of America Co sponsors trial with 3
University of Southern Denmark Co sponsors trial with 1
Autism Speaks Co sponsors trial with 1
Horizon Health Network Co sponsors trial with 1
University of Iowa Co sponsors trial with 1

Latest dated events (317)

Shown in this order: newest first.

Latest dated events
Date Event Source
2026-12-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-10 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-10 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-10 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-10 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))

Biomarker capability evidence (39)

Shown in this order: tier desc, then gene symbol.

Biomarker capability evidence
Gene Role Evidence
BPIFA4P Trial collaborator Named in trial inclusion criteria
CHAMP1 Trial collaborator Named in trial inclusion criteria
CREB3L1 Trial sponsor Named in trial inclusion criteria
FGR Trial collaborator Named in trial inclusion criteria
LBP Trial collaborator Named in trial inclusion criteria

Biomarkers this organization publishes on (93)

Shown in this order: most publications first.

Biomarkers this organization publishes on
Biomarker Publications
IL10 3
INS 3
TGFB1 3
CD4 2
DMD 2

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.